Fed. Circ. Affirms PTAB Ax Of AbbVie's Humira Patent
Law360 (January 8, 2020, 4:06 PM EST) -- The Federal Circuit on Tuesday summarily affirmed the Patent Trial and Appeal Board's inter partes review decisions invalidating a key patent for AbbVie Biotechnology Ltd.'s top-selling Humira, an immunosuppressant drug that brought in more than $13.6 billion in U.S. sales revenue in 2018.
AbbVie's Humira patent has been challenged by numerous pharmaceutical companies planning to launch biosimilar versions of Humira, reported to be the world's best-selling pharmaceutical. The drug, which saw nearly $20 billion in global sales in 2018, is widely used to treat rheumatoid arthritis.
AbbVie's U.S. Patent No. 8,889,135 covers methods of treating rheumatoid arthritis with a 40-milligram injection...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!